Results 51 to 60 of about 67,556 (137)

Knockdown of mitotically associated long non‐coding RNA dysregulates endothelial functions, transcriptome and proteome

open access: yesThe Journal of Physiology, Volume 604, Issue 22, Page 9333-9385, 15 November 2026.
Abstract figure legend Downregulation of mitotically associated long non‐coding RNA (MANCR) disturbs transcriptome and proteome in endothelial cells, possibly leading to endothelial and vascular dysfunction in preeclampsia. Abstract Preeclampsia (PE) is a hypertensive disorder during pregnancy, which is characterized by a wide spectrum of endothelial ...
Si‐Yan Zhang, Chi Zhou, Jing Zheng
wiley   +1 more source

Related Article from NF1 Inactivation Revs Up Ras in Adult Acute Myelogenous Leukemia

open access: yes, 2010
Related Article from NF1 Inactivation Revs Up Ras in Adult Acute Myelogenous ...
Ann Mullally (558873)   +1 more
core   +1 more source

Analysis of Chromosomal Aberrations and FLT3 gene Mutations in Childhood Acute Myelogenous Leukemia Patients

open access: yes, 2012
Objective: To identify the well-known common translocations and FLT3 mutations in childhood acute myelogenous leukemia (AML) patients in ...
Agaoglu, Leyla   +12 more
core   +1 more source

Bosutinib in the management of chronic myelogenous leukemia

open access: yes, 2013
Gunhild Keller-von Amsberg, Philippe SchafhausenDepartment of Hematology and Oncology and, Stem Cell Transplantation and Pulmonology Division, Oncological Center, University Hospital Hamburg-Eppendorf, Hamburg, GermanyAbstract: Bosutinib (SKI-606) is an ...
Keller-von Amsberg G, Schafhausen P
core  

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia

open access: yes, 2008
Judith E Karp1, Jeffrey E Lancet21Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA; 2H.
Jeffrey E Lancet, Judith E Karp
core  

Spotlight on nilotinib in the treatment of chronic myelogenous leukemia

open access: yes, 2014
Stephen Harnicar, Sherry Mathew Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA Abstract: Nowhere has targeted therapy been more successful in the hematologic malignancy arena than chronic myelogenous leukemia (CML). By
Harnicar S, Mathew S
core  

Bone marrow stromal cells in acute promyelocytic leukaemia: comparison with other acute myelogenous leukaemia subtypes.

open access: yes, 2000
Bone marrow stromal cells in acute promyelocytic leukaemia: comparison with other acute myelogenous leukaemia ...
Castoldi G.L.   +7 more
core  

ERLOTINIB IN A PATIENT WITH ACUTE MYELOGENOUS LEUKEMIA AND CONCOMITANT NON-SMALL-CELL LUNG CANCER

open access: yes, 2008
ERLOTINIB IN A PATIENT WITH ACUTE MYELOGENOUS LEUKEMIA AND CONCOMITANT NON-SMALL-CELL LUNG ...
ALTAVILLA, Giuseppe   +2 more
core  

Supplementary Table S2 from Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia

open access: yes, 2017
Characteristics of patients with chronic myelogenous leukemia.
Ke Ding (309244)   +5 more
core   +1 more source

Case 37-1994: Juvenile chronic myelogenous leukemia

open access: yes, 1995
To the Editor: The case report in the October 13 issue1 describes a newborn boy with juvenile chronic myelogenous leukemia that was diagnosed on the basis of “an open-liver biopsy, which revealed an extensive...
Grabowski E. F.   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy